Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5699142 | 0.75 | MEN1 (0.31) | HTT | |
| SCHEMBL14861504 | 0.69 | ALDH1A1 (0.39) | ERBB2EGFRALDH1A1MAPTRAB9A | |
| SCHEMBL14857685 | 0.69 | ALDH1A1 (0.39) | ERBB2EGFRALDH1A1MAPTRAB9A | |
| SCHEMBL839679 | 0.67 | CA12 (0.38) | ERBB2EGFRALDH1A1MAPT | |
| SCHEMBL12367893 | 0.67 | ALDH1A1 (0.37) | ERBB2EGFRALDH1A1MAPTHTT | |
| Hydrochloric Acid SCHEMBL16540425 | 0.66 | ALDH1A1 (0.36) | ERBB2EGFRALDH1A1MAPT | |
| SCHEMBL5734957 | 0.66 | HTR3E (0.44) | ALDH1A1MAPT | |
| SCHEMBL5647058 | 0.66 | NCF1 (0.43) | ALDH1A1MAPTHTT | |
| SCHEMBL108973 | 0.65 | — | — | |
| SCHEMBL21861906 | 0.64 | MEN1 (0.42) | ERBB2EGFRALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385065-B2 | Antibacterial compounds | REDX PHARMA PLC (GB) | 2019-08-20 | — | — | US | disclosed |
| US-10385065-B2 | Antibacterial compounds | REDX PHARMA PLC (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20170158708-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158708-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158708-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-06-08 | — | — | US | disclosed |
| WO-2017046603-A1 | ANTIBACTERIAL COMPOUNDS AND NEW USES THEREOF | REDX PHARMA PLC (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046606-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046605-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-03-23 | — | — | WO | disclosed |
| EP-3129386-A1 | ANTIBACTERIAL COMPOUNDS | Redx Pharma PLC (GB) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015155549-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2015-10-15 | — | — | WO | disclosed |
| EP-1070713-B1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2006-10-18 | — | — | EP | disclosed |
| US-6335447-B1 | BACTERICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| EP-1070713-A1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158708-A1 | ANTIBACTERIAL COMPOUNDS | ABCC1, SLC11A2, NQO2 | ERBB2 2687/4885EGFR 1616/4885EPHA2 4813/4885 |
| US-10385065-B2 | Antibacterial compounds | ABCC1, SLC11A2, NQO2 | ERBB2 2687/4885EGFR 1616/4885EPHA2 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.